Therefore, the knockdown of ANO1 can ameliorate obesity, hepatic glucose metabolism disorders, and steatosis caused by a high‐fat diet, and ANO1 may be a potential therapeutic target for NAFLD (Figure 2). Here, ANO1 is linked to obesity due to melanocortin 4 receptor deficiency.